Literature DB >> 10985567

Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography.

R M Hollanders1, E W van Ewijk-Beneken Kolmer, D M Burger, E W Wuis, P P Koopmans, Y A Hekster.   

Abstract

A sensitive and rapid high-performance liquid chromatography method has been developed to measure the levels of the HIV-1 non-nucleoside reverse transcriptase inhibitor nevirapine in human plasma. The sample pre-treatment consists of a protein precipitation with perchloric acid. A Hypersil ODS column is used at ambient temperature and a wavelength of 280 nm is used for ultraviolet detection. The mobile phase contains acetonitrile and a 60 mM phosphate buffer pH 4.5 (30:70, v/v). The detection limit of the method is 0.05 mg/l using 150 microl of plasma. The lower and upper limit of quantitation are 0.1 mg/l and 10 mg/l, respectively. The average recovery of nevirapine is 101.8% with a variation of 4.6%. The average inter-assay precision is 2.4%, the average intra-assay precision 2.9% and the average accuracy 97%.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985567     DOI: 10.1016/s0378-4347(00)00231-0

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  9 in total

1.  Evaluation of antiretroviral therapy results in Blantyre, Malawi.

Authors:  J J van Oosterhout; N Bodasing; J J Kumwenda; C Nyirenda; J Mallewa; P R Cleary; M P de Baar; R Schuurman; D M Burger; E E Zijlstra
Journal:  Malawi Med J       Date:  2005-12       Impact factor: 0.875

2.  Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.

Authors:  Tim R Cressey; Baralee Punyawudho; Sophie Le Coeur; Gonzague Jourdain; Chalermpong Saenjum; Edmund V Capparelli; Kanokwan Jittayanun; Siriluk Phanomcheong; Anita Luvira; Thitiporn Borkird; Achara Puangsombat; Leon Aarons; Pra-Ornsuda Sukrakanchana; Saik Urien; Marc Lallemant
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

3.  Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.

Authors:  Weerawat Manosuthi; Somnuek Sungkanuparph; Preecha Tantanathip; Wiroj Mankatitham; Aroon Lueangniyomkul; Supeda Thongyen; Boonchuay Eampokarap; Sumonmal Uttayamakul; Pawita Suwanvattana; Samroui Kaewsaard; Kiat Ruxrungtham
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

4.  Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.

Authors:  Sumonmal Uttayamakul; Sirirat Likanonsakul; Weerawat Manosuthi; Nuanjun Wichukchinda; Thareerat Kalambaheti; Emi E Nakayama; Tatsuo Shioda; Srisin Khusmith
Journal:  AIDS Res Ther       Date:  2010-03-26       Impact factor: 2.250

5.  A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons.

Authors:  Chen Ren; Patty Fan-Havard; Natalia Schlabritz-Loutsevitch; Yonghua Ling; Kenneth K Chan; Zhongfa Liu
Journal:  Biomed Chromatogr       Date:  2010-07       Impact factor: 1.902

6.  Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

Authors:  Louisa Pollock; Laura Else; Goenke Poerksen; Elizabeth Molyneux; Peter Moons; Sarah Walker; William Fraser; David Back; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2009-10-06       Impact factor: 5.790

7.  Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients.

Authors:  Stéphane Azoulay; Marie-Claire Nevers; Christophe Créminon; Laurence Heripret; Jacques Durant; Pierre Dellamonica; Jacques Grassi; Roger Guedj; Danièle Duval
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

8.  Simple, precise and accurate HPLC method of analysis for nevirapine suspension from human plasma.

Authors:  S Halde; A Mungantiwar; M Chintamaneni
Journal:  Indian J Pharm Sci       Date:  2011-07       Impact factor: 0.975

9.  Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.

Authors:  Andrzej Bienczak; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; A Sarah Walker; Andrew Owen; Diana M Gibb; David Burger; Helen McIlleron; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2016-10-05       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.